Older mother hiking with daughter, embrace, trust, support, blood cancer, oncology, Clinical Genomics

Oncology | Blood Cancer

Level up MPN diagnosis and care

What are MPNs?

Myeloproliferative neoplasms (MPNs) are a class of rare but potentially life-threatening blood cancers. They start out due to a mutation in a bone marrow stem cell, which then leads to an overproduction of blood cells.

The major MPN subtypes are Essential Thrombocythemia (ET), Myelofibrosis (MF) and Polycythemia Vera (PV). For many patients, living with an MPN means a reduced quality of life and shortened survival.*

What’s behind MPNs?

Myeloproliferative neoplasms are characterized by specific molecular markers.

Most patients with an MPN will have mutations in one of these three genes—JAK2, CALR and MPL.**

Accurate diagnosis and effective care are dependent on quick identification of these biomarkers.

female young scientist, lab worker, tablet

Now it's easier to follow the WHO guidelines for MPN diagnosis

Molecular testing is now routine in the clinical management of MPN patients. It helps in establishing the correct diagnosis and monitoring patients’ molecular response. The tests provide useful medical information to aid clinicians when designing patients’ personalized treatment strategy.

European biomedical lab experience: Improved leukemia patient care with molecular analysis

Learn how a European laboratory partnered with QIAGEN to implement an end-to-end solution for JAK2 V617F and CALR testing, using a single blood sample.

Watch webinar

Anna Tarasewicz and Munyoro Guvamatanga webinar speaker

Simplified JAK2 mutation testing

Interested in reliable, sensitive and specific JAK2 V617F detection? Find out how our JAK2 testing kits guarantee this.

Find out more

References:

* The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey (2017).https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569657/ (accessed May 10, 2022)

** The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (2016). https://ashpublications.org/blood/article/127/20/2391/35255/The-2016-revision-to-the-World-Health-Organization (accessed May 10, 2022)